Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,451Revenue $M0Net Margin (%)0Z-Score6.0
Enterprise Value $M1,268EPS $-2.9Operating Margin %0F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book8.710-y EBITDA Growth Rate %0Quick Ratio13.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio13.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-77.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-98.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M36.1ROI % (ttm)-77.5Gross Margin Increase y-yN

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

TSRO is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Armitage James ODirector 2014-12-12Buy1,000$38.165.42view
Alleva Lawrence MDirector 2014-09-29Buy1,100$26.1753.73view
Alleva Lawrence MDirector 2013-07-31Buy1,449$34.3317.19view
BARRETT M JAMES10% Owner 2013-06-10Sell415$40.49-0.64view
Weller Harry R10% Owner 2013-06-10Sell560$41.45-2.94view
BARRETT M JAMES10% Owner 2013-06-05Sell3,583$393.15view
BASKETT FOREST10% Owner 2013-06-05Sell4,296$39.152.76view
SANDELL SCOTT D10% Owner 2013-06-05Sell4,412$39.312.34view
DRANT RYAN D10% Owner 2013-06-05Sell4,163$39.162.73view
BARRIS PETER J10% Owner 2013-06-05Sell3,583$393.15view

Press Releases about TSRO :

    Quarterly/Annual Reports about TSRO:

    News about tsro:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Venture-Backed Biotech Today: Reflections On Exits, Funding And Startup Formation Jan 22 2015
    TESARO, INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits Jan 12 2015
    CORRECTING and REPLACING -- TESARO Announces Expansion of Niraparib Clinical Program and Outlines... Jan 12 2015
    TESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 12 2015
    TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones... Jan 12 2015
    TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones... Jan 12 2015
    Pfizer Licenses Opko's Long-Acting Growth Hormone Dec 15 2014
    TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody... Dec 02 2014
    TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody... Dec 02 2014
    TESARO to Present at the 2014 Deutsche Bank BioFEST Nov 25 2014
    TESARO to Present at the Nasdaq 31st Investor Program Nov 25 2014
    TESARO to Present at the Nasdaq 31st Investor Program Nov 25 2014
    Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test Nov 21 2014
    TESARO and Myriad Announce Companion Diagnostics Collaboration Nov 20 2014
    TESARO and Myriad Announce Companion Diagnostics Collaboration Nov 20 2014
    TESARO, INC. Financials Nov 14 2014
    TESARO to Present at the Jefferies 2014 Global Healthcare Conference Nov 12 2014
    TESARO to Present at the Jefferies 2014 Global Healthcare Conference Nov 12 2014
    TESARO, INC. Files SEC form 10-Q, Quarterly Report Nov 06 2014
    Tesaro beats 3Q profit forecasts Nov 06 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK